Clinical Trials

22 enrolled

Lung Neoplasms

NCT05994339 2023-08-29

Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer

Phase 2/3 Unknown

40 enrolled

Lung Neoplasms

NCT05826483 2023-04-24

Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status

Phase 1 Unknown

20 enrolled

Lung Neoplasms

NCT04922138 2023-04-21

APPOINT

104 enrolled

Lung Neoplasms

NCT04519983 2023-03-20

Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs

40 enrolled

Lung Neoplasms

NCT05430386 2023-02-14

Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC

Phase 1 Unknown

174 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02981108 2023-01-23

A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC

Phase 1/2 Unknown

364 enrolled 29 charts

Carcinoma, Non-Small-Cell Lung

NCT03849768 2023-01-20

A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients

429 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung

NCT05223595 2022-02-04

A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC

Phase 1 Unknown

42 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04755738 2021-09-05

MWA

234 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04778800 2021-08-31

A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)

Phase NA Unknown

60 enrolled

CNS

Brain Neoplasms, Meningeal Carcinomatosis

NCT04978753 2021-07-27

the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer

54 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04951648 2021-07-07

A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation

220 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04952168 2021-07-07

Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

26 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04944069 2021-06-29

ATTRACT

Phase NA Unknown

69 enrolled

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT04905550 2021-06-02

Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC

50 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04882345 2021-05-11

ACTIVE

40 enrolled

Lung Neoplasms

NCT04643847 2020-11-25

A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases

47 enrolled

CNS

Brain Neoplasms

NCT04500704 2020-08-05

ACROSS1

166 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04500717 2020-08-05

ACROSS2

460 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04455594 2020-07-02

ANSWER

168 enrolled